Pfizer provides 2025 revenue guidance $61-64B, adj. EPS $2.80-3.00

PFIZER INC

Full-year 2025 revenue guidance range of $61.0 to $64.0 billion, with operational growth approximately flat to 5% year-over-year.
Full-year 2025 adjusted diluted EPS guidance range of $2.80 to $3.00, reflecting operational growth of 10% to 18%.
Achieved goal of $4.0 billion in net cost savings through 2024; expects an additional $500 million in savings in 2025.
First phase of manufacturing optimization program on track to deliver initial net cost savings in latter part of 2025.
Reaffirmed full-year 2024 guidance: revenue $61-64B, adjusted EPS $2.75-2.95.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.